Market: NMS |
Currency: USD
Address: 4660 La Jolla Village Drive
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
📈 Revelation Biosciences, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$85.00
-
Upside/Downside from Analyst Target:
13,059.93%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-03-06
-
EPS Estimate:
-3.66
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.333333 |
- |
2025-07-07 |
- |
Stock split |
| $0.062500 |
- |
2025-01-28 |
- |
Stock split |
|
Total Amount for 2025: $0.395833 |
| 2024 |
- |
$0.033333 |
- |
2024-01-25 |
- |
Stock split |
|
Total Amount for 2024: $0.033333 |
| 2023 |
- |
$0.028571 |
- |
2023-02-01 |
- |
Stock split |
|
Total Amount for 2023: $0.028571 |
📅 Earnings & EPS History for Revelation Biosciences, Inc.
| Date | Reported EPS |
|---|
| 2026-03-05 (estimated upcoming) | - |
| 2025-11-06 | -7.08 |
| 2025-08-08 | -28.04 |
| 2025-05-08 | -25.32 |
| 2025-03-06 | -59.76 |
| 2024-11-08 | -161.28 |
| 2024-08-09 | -984.96 |
| 2024-05-10 | -472.32 |
| 2024-03-22 | -6859.07 |
| 2023-11-09 | -2488.78 |
| 2023-08-11 | -1854.72 |
| 2023-05-22 | -2913.41 |
| 2023-03-30 | -12904.14 |
| 2022-11-10 | -12096.03 |
| 2022-08-15 | -24192.05 |
| 2022-05-16 | -94752.2 |
📰 Related News & Research
No related articles found for "revelation biosciences".
